The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 5031-5047

  Berezhkovskiy, Leonid M ^a  

^a GENENTECH INC   (United States)

Author keywords

Central elimination; Hepatic clearance; Hepatic transport; Mean residence time; Physiologically based pharmacokinetic model; Steady state volume of distribution; Terminal half life; Terminal volume of distribution

Indexed keywords

CARRIER PROTEIN; DRUG;

ACCURACY; ARTICLE; CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; HYDROPHILICITY; LIPOPHILICITY; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; TRANSPORT KINETICS;

EID: 80053231859     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22696     Document Type: Article

References (28)

1. Gillette JR. 1971. Factors affecting drug metabolism. Ann NY Acad Sci 179:43-66.
2. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, Tsuji A. 1999. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharm Res 16:1213-1218.
3. Shitara Y, Horie T, Sugiyama Y. 2006. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
4. Vanwert AL, Bailey RM, Sweet DH. 2007. Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 293:F1332-F1341.
5. Grover A, Benet LZ. 2009. Effects of drug transporters on volume of distribution. AAPS J 11:250-261.
6. Baker M, Parton T. 2007. Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica 37:1110-1134.
7. Berezhkovskiy LM. 2010. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood- tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci 99:475-485.
8. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
9. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
10. Berezhkovskiy LM. 2011. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 100:1167-1183.
11. Veng-Pedersen P. 2001. Noncompartmentally-based pharmacokinetic modeling. Adv Drug Deliv Rev 48:265-300.
12. Berezhkovskiy L.M. 2007. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 96:3432-3443.
13. Berezhkovskiy LM. 2009. Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters. J Pharm Sci 98:748-762.
14. Oppenheimer JH, Schwartz JL, Surks MI. 1975. Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis. J Clin Edocrin Metab 41:319-324.
15. Benet LZ, Galeazzi RL. 1979. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68(8):1071-1074.
16. ss. J Pharm Sci 96:1638-1652.
17. Niazi S. 1976. Volume of distribution as a function of time. J Pharm Sci 65:452-454.
18. Wagner JG. 1976. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4:443-467.
19. Berezhkovskiy LM. 2011. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional non-compartmental equations and the prediction of the steady state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci 100:2482-2497.
20. Korn GA, Korn TM. 1961. Mathematical handbook for scientists and engineers. New York: McGraw-Hill, Inc.
21. Veng-Pedersen P. 1980. Model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response I: Theoretical analysis. J Pharm Sci 69(3):298-305.
22. Berezhkovskiy LM. 2008. Prediction of the possibility of the second peak of drug plasma concentration time curve after iv bolus administration from the standpoint of the traditional multi-compartmental linear pharmacokinetics. J Pharm Sci 97:2385-2393.
23. Turner D, Ed. 2008. Simcyp population-based ADME simulator user manual. Version 8. Sheffield, UK: Simcyp Limited, Blades Enterprise Centre, pp 232.
24. Fagerholm U. 2009. Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica 39:57-71.
25. Blouin A. 1977. Morphometry of liver sinusoidal cells. In Kupffer cells and other liver sinusoidal cells; Wisse E, Knook DL, Eds.
26. Bass L, Keiding S. 1988. Physiologically based models and strategic experiments in hepatic pharmacology. Biochem Pharmacol 37:1425-1431.
27. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8- mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
28. Mück W. 2000. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 39:99-116.